DNAJB12

Across TCGA pan-cancer cohorts, DNAJB12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAJB12 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher DNAJB12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJB12 expression acts as an unfavorable survival marker.

KICH, COAD, and READ are the cancer types where DNAJB12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.043	0.971	<.001	33	view →
COAD	OS	Median	All	0.461	0.808	.012	9	view →
READ	DFS	Median	All	0.111	0.799	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	0.138	0.494	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAJB12–KICH (DFS)

Open the KICH breakdown →